Print Page     Close Window     

SEC Filings

6-K
AC IMMUNE SA filed this Form 6-K on 06/28/2017
Entire Document
 
 

© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 22 Misfolded Tau as one major cause of neurodegeneration AC Immune’s Tau therapies intervene at key points in the disease pathway Healthy cell Affected cell Recipient cell Nucleus Misfolded Tau Nucleus Nucleus Normally folded Tau Nucleus Reverse misfolding Inhibit spreading Promote disaggregation Prevent seeding Morphomer Tau ACI - 35 Anti - Tau antibody Tau PET - imaging agent for companion diagnosis Morphomer Tau

 

© AC Immune 2015